Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows Sells 12,500 Shares

Spyre Therapeutics, Inc. (NASDAQ:SYRE) CFO Scott Burrows sold 12,500 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $71.37, for a total transaction of $892,125.00. Following the transaction, the chief financial officer directly owned 97,994 shares in the company, valued at approximately $6,993,831.78. This represents a 11.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Spyre Therapeutics Stock Performance

SYRE stock opened at $69.42 on Friday. Spyre Therapeutics, Inc. has a 52 week low of $12.28 and a 52 week high of $76.00. The firm’s fifty day moving average is $51.75 and its 200 day moving average is $37.36. The firm has a market cap of $5.47 billion, a P/E ratio of -33.38 and a beta of 3.12.

Spyre Therapeutics (NASDAQ:SYRE) last released its earnings results on Thursday, February 19th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.04). As a group, analysts forecast that Spyre Therapeutics, Inc. will post -2.8 EPS for the current year.

Analyst Ratings Changes

SYRE has been the subject of several analyst reports. Wedbush increased their price target on shares of Spyre Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, April 13th. JonesTrading increased their price target on shares of Spyre Therapeutics from $64.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, April 17th. Leerink Partners increased their price target on shares of Spyre Therapeutics from $49.00 to $106.00 and gave the company an “outperform” rating in a research report on Monday, April 13th. Wells Fargo & Company increased their price target on shares of Spyre Therapeutics from $50.00 to $90.00 and gave the company an “overweight” rating in a research report on Tuesday, April 14th. Finally, Wall Street Zen cut shares of Spyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, April 26th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Spyre Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $85.08.

Trending Headlines about Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Yahoo Finance ran a feature asking whether Spyre is one of the small-cap stocks “on fire,” highlighting recent momentum and investor interest that can support valuation and liquidity. Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?
• Neutral Sentiment: Spyre’s Compensation Committee approved inducement stock options totaling 20,800 shares for four non-executive hires — a common hiring tool; dilution is small but notable if hiring accelerates. Spyre Therapeutics Announces Grants of Inducement Awards
• Negative Sentiment: CEO Cameron Turtle sold 15,000 shares at ~$71.37 under a 10b5-1 plan (?$1.07M); although planned, large insider sales can signal executives taking profits after the run-up. SEC Form 4 — Cameron Turtle
• Negative Sentiment: Insider Sheldon Sloan sold 78,333 shares at ~$71.50 (~$5.6M), reducing his position by half via a 10b5-1 plan — a large, headline-grabbing sale that likely pressured sentiment. SEC Form 4 — Sheldon Sloan
• Negative Sentiment: CFO Scott L. Burrows sold 12,500 shares at ~$71.37 (~$892k) under a 10b5-1 plan, trimming ~11% of his holdings — another insider sale adding to downward pressure. SEC Form 4 — Scott L. Burrows

Institutional Investors Weigh In On Spyre Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Summit Securities Group LLC purchased a new stake in shares of Spyre Therapeutics in the 1st quarter worth about $28,000. Russell Investments Group Ltd. lifted its position in Spyre Therapeutics by 2,881.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after acquiring an additional 4,092 shares during the period. Persistent Asset Partners Ltd purchased a new position in Spyre Therapeutics during the 4th quarter valued at about $74,000. Tower Research Capital LLC TRC increased its stake in Spyre Therapeutics by 182.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock valued at $86,000 after purchasing an additional 3,725 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Spyre Therapeutics by 61.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,770 shares of the company’s stock valued at $124,000 after purchasing an additional 1,435 shares in the last quarter. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.